Importing Medical Devices vs Manufacturing Locally in China: Which Strategy?

Quick definition: Foreign medical device companies entering China face a fundamental strategic choice: import finished devices (via a Chinese legal agent and NMPA import registration) or establish local manufacturing (through a WFOE (外商独资企业, waishang duzi qiye) or joint venture). The decision carries major implications for cost structure, regulatory burden, supply chain risk, and market access. Currently, 82% of foreign medical devices sold in China are imported (NMPA 2024 data), but the share of locally manufactured devices is growing at 14% CAGR as the government pushes for localization through procurement preferences and tax incentives.

Why This Matters

China’s medical device market is projected to reach $98 billion by 2027 (IQVIA Medical Technology Report 2024), making it the second-largest market globally. But the regulatory and operational environment has shifted dramatically. Since 2020, the Chinese government has introduced preferential procurement policies favoring locally manufactured devices, tariffs on imported devices have fluctuated, and supply chain disruptions during COVID highlighted the risks of relying on overseas production. For foreign executives, the import-vs-local-manufacture decision is no longer purely a cost calculation — it’s a strategic market access decision that affects revenue potential, customer perception, and long-term competitive position.

Head-to-Head: Importing vs Local Manufacturing

1. Regulatory Requirements

• Import route: Requires NMPA import device registration (Class I/II/III depending on device). The foreign manufacturer must designate a Chinese legal agent (China Agent, 代理人) who holds joint liability for the product. The foreign factory must pass an NMPA GMP inspection (for Class II/III). The registration certificate is issued to the foreign legal manufacturer, valid for 5 years. Key requirement: Chinese-language IFU and labeling must be submitted with the registration dossier.
• Local manufacturing route: Requires establishing a China-based legal entity (typically a WFOE with a medical device manufacturing license). The entity applies for NMPA registration as a domestic manufacturer, which follows the same classification rules but may qualify for expedited review under certain provincial programs. The local factory must obtain a Medical Device Production License (医疗器械生产许可证) from the provincial NMPA — a separate process taking 3–6 months.
• Key difference: Import registration certifies the product (with the foreign manufacturer as the certificate holder). Local manufacturing certifies the manufacturer (the Chinese entity). A locally manufactured device can be listed on government procurement catalogs that are restricted to domestic products — a significant market access advantage.

2. Cost Structure

• Import route upfront costs: NMPA registration ($50,000–$450,000 depending on class), Chinese legal agent fees ($15,000–$30,000/year), import tariffs (4–12% depending on device category, plus 13% VAT), logistics and warehousing ($5,000–$20,000/month). Total first-year cost: $100,000–$600,000.
• Local manufacturing upfront costs: WFOE setup ($20,000–$50,000), facility lease and fit-out ($200–$500/sq.m in a medical device park), manufacturing equipment ($500,000–$3M depending on complexity), hiring and training ($100,000–$300,000/year for 10–30 staff), NMPA manufacturing license ($5,000–$15,000), product registration at domestic rates ($15,000–$150,000). Total first-year cost: $800,000–$4M.
• Breakeven analysis: For most Class II devices, the breakeven point is 3–5 years with annual sales of $2M–$5M. For Class III devices with higher margins, breakeven can come in 2–4 years at annual sales of $1M–$3M. Below these thresholds, importing is almost always more cost-effective.

3. Market Access and Procurement Advantages

• Import route: Can sell to private hospitals, foreign-invested hospitals, and some public hospitals. However, since 2021, more Chinese public hospitals have implemented “domestic purchase preference” policies that require medical devices in certain categories to be locally manufactured. The Ministry of Finance’s 2024 procurement guidelines explicitly give a 10–20% price preference to domestically manufactured medical devices in public tenders. Imported devices are effectively at a 10–20% price disadvantage.
• Local manufacturing route: Qualifies as a “domestic product” (国产产品) in government procurement tenders. This opens access to the ~60% of China’s medical device market that flows through public hospital procurement. Eligible for Volume-Based Procurement (VBP, 集采) programs — the government’s bulk purchasing scheme that offers guaranteed volumes in exchange for lower prices. VBP participation can increase market share by 200–400% within 12 months, though at 30–50% lower unit prices.
• Quantified impact: A 2024 McKinsey analysis found that foreign manufacturers with local production in China achieved an average 23% higher market share in public hospitals compared to those relying solely on imports. In categories like CT scanners and MRI machines, the gap was 35%.

4. Supply Chain and Risk Management

• Import route risks: (a) Tariff escalation — US–China trade tensions have resulted in retaliatory tariffs as high as 25% on US-made devices; (b) Shipping delays — 2023–2024 Red Sea disruptions added 14–21 days to Europe–China shipping times; (c) Currency fluctuation — the RMB depreciated 8% against the USD in 2023–2024, directly reducing import profit margins; (d) Regulatory changes — import registration renewal requirements can cause supply gaps if not managed carefully.
• Local manufacturing risks: (a) IP protection — despite improvements, technology transfer risks remain significant, especially for manufacturing processes involving proprietary know-how; (b) Regulatory compliance — maintaining a Chinese manufacturing facility requires ongoing NMPA compliance, environmental permits, and labor law adherence; (c) Higher fixed costs — the facility must maintain production volume to stay economical; (d) Exit complexity — dissolving a WFOE and closing a factory takes 6–18 months and can cost $50,000–$200,000.
• Risk comparison: Importing offers greater flexibility and lower exit costs but exposes the manufacturer to trade, currency, and supply chain disruptions. Local manufacturing offers more stable market access but ties the company to a fixed physical footprint in China.

5. Speed to Market

• Import route: 9–24 months from decision to first sale (Class I: 3–6 months, Class II: 9–15 months, Class III: 14–24 months). No facility construction required. The manufacturer uses its existing overseas production capacity.
• Local manufacturing route: 18–36 months from decision to first sale. Includes: WFOE registration (1–3 months), facility lease and fit-out (4–8 months), equipment procurement and installation (3–6 months), manufacturing license application (3–6 months), product registration (9–15 months for Class II, 14–24 months for Class III).
• Speed implication: Importing can get you to market 9–12 months faster on average — a significant advantage in fast-growing device categories where first-mover status matters. However, once established, local manufacturers can launch subsequent products more quickly (3–6 months to add a new SKU vs 9–15 months for a new import registration).

Decision Data Table

Pitfalls to Avoid

Real-World Case Studies

Case A: US Dental Implant Company — Import-First Strategy

A US manufacturer of premium dental implants entered China through the import route, registering 3 Class II product lines through a Shanghai-based legal agent. Total first-year cost: $145,000. Time to first sale: 13 months. Within 2 years, they achieved $1.8M annual revenue through private dental chains and top-tier public hospital stomatology departments. However, they were excluded from 4 provincial VBP programs. In 2025, they are evaluating a joint venture assembly facility in Suzhou to qualify for domestic status. Their strategy: import first to prove demand, then localize once annual revenue exceeds $3M.

Case B: German Diagnostic Equipment Manufacturer — Local Manufacturing from Day One

A German manufacturer of clinical chemistry analyzers established a WFOE factory in Suzhou Industrial Park from inception. Investment: $2.8M including facility, equipment, and 35 local staff. Time to first sale: 22 months. Within 18 months of production, they won VBP contracts in 7 provinces, increasing volume by 340%. Unit prices under VBP were 55% lower than their import-mix competitors, but total revenue grew to $4.2M/year. Their domestic status also made them eligible for the 15%高新技术企业 (High-Tech Enterprise) tax rate, reducing their effective corporate tax from 25% to 15%.

Case C: Japanese Ophthalmic Device Maker — Hybrid Approach

A Japanese manufacturer of ophthalmic surgical microscopes initially imported their premium models (Class II, Jiangsu agent) while negotiating a technology partnership with a Suzhou-based contract manufacturer for mid-range models. The import line generated $2.1M/year serving top-tier hospitals. The local manufacturing JV, operational after 18 months, focused on the VBP-eligible mid-range segment and generated $3.5M/year at lower margins but higher volume. Combined profit margin: 22%, versus 30% for the import-only line — but the JV opened doors to 47 additional hospitals that the import line could not access.

Which Strategy Should You Choose?